NCT07150975View on ClinicalTrials.gov

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Obesity/Overweight in Adult
Interventions
DRUG

GZR18

Administered SC

DRUG

Semaglutide(Wegovy® )

Administered SC

Sponsors
All Listed Sponsors
lead

Gan & Lee Pharmaceuticals.

INDUSTRY